Published in PLoS One on February 05, 2013
Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals. Exp Ther Med (2013) 0.78
Febuxostat improves outcome in a rat model of cancer cachexia. J Cachexia Sarcopenia Muscle (2015) 0.76
DOCA-salt hypertension impairs artery function in rat middle cerebral artery and parenchymal arterioles. Microcirculation (2016) 0.75
Experimental and clinical nephroprotection by the xanthine oxidase inhibitor febuxostat. Naunyn Schmiedebergs Arch Pharmacol (2016) 0.75
Uric acid and cardiovascular risk. N Engl J Med (2008) 12.20
Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med (2005) 7.24
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA (2008) 5.59
Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension (2003) 5.47
Hyperuricemia induces endothelial dysfunction. Kidney Int (2005) 5.36
Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension (2001) 4.41
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev (2006) 3.27
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum (2008) 3.25
Febuxostat. Drugs (2008) 2.78
Endothelin-1-induced oxidative stress in DOCA-salt hypertension involves NADPH-oxidase-independent mechanisms. Clin Sci (Lond) (2006) 1.87
Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase. Life Sci (2005) 1.76
Inactivation of nitric oxide by uric acid. Nucleosides Nucleotides Nucleic Acids (2008) 1.59
Oxidative stress and hypertension: current concepts. Curr Hypertens Rep (2010) 1.54
An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem (2002) 1.50
Antioxidant treatment prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. Hypertension (2005) 1.42
Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome. Am J Physiol Renal Physiol (2008) 1.38
Xanthine oxidase activity associated with arterial blood pressure in spontaneously hypertensive rats. Proc Natl Acad Sci U S A (1998) 1.19
Effect of febuxostat on the progression of renal disease in 5/6 nephrectomy rats with and without hyperuricemia. Nephron Physiol (2008) 1.13
Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant (2007) 1.13
Apocynin but not allopurinol prevents and reverses adrenocorticotropic hormone-induced hypertension in the rat. Am J Hypertens (2005) 1.13
Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol (2008) 1.08
Tempol lowers blood pressure and sympathetic nerve activity but not vascular O2- in DOCA-salt rats. Hypertension (2004) 1.04
Association between endothelial dysfunction and hyperuricaemia. Rheumatology (Oxford) (2010) 1.03
Increased reactive oxygen species contributes to kidney injury in mineralocorticoid hypertensive rats. J Physiol Pharmacol (2006) 0.98
Role of xanthine oxidase in dexamethasone-induced hypertension in rats. Clin Exp Pharmacol Physiol (2007) 0.97
Renal xanthine oxidoreductase activity during development of hypertension in spontaneously hypertensive rats. J Hypertens (2004) 0.96
Allopurinol reduces neointimal hyperplasia in the carotid artery ligation model in spontaneously hypertensive rats. Hypertens Res (2006) 0.92
2,3',4,5'-Tetramethoxystilbene prevents deoxycorticosterone-salt-induced hypertension: contribution of cytochrome P-450 1B1. Am J Physiol Heart Circ Physiol (2010) 0.87
Associations of hypertension and its complications with variations in the xanthine dehydrogenase gene. Hypertens Res (2008) 0.85
Allopurinol attenuates L-NAME induced cardiomyopathy comparable to blockade of angiotensin receptor. Histol Histopathol (2008) 0.83
The efficacy and safety of febuxostat for urate lowering in gout patients ≥65 years of age. BMC Geriatr (2012) 0.82
Effects of allopurinol, a xanthine oxidase inhibitor, on renal injury in hypercholesterolemia-induced hypertensive rats. Blood Press (2005) 0.82
Women with gout: efficacy and safety of urate-lowering with febuxostat and allopurinol. Arthritis Care Res (Hoboken) (2012) 0.81
2011 recommendations for the diagnosis and management of gout and hyperuricemia. Phys Sportsmed (2011) 0.77
Allopurinol does not decrease blood pressure or prevent the development of hypertension in the deoxycorticosterone acetate-salt rat model. J Cardiovasc Pharmacol (2010) 0.77
Circulating angiotensin II and dietary salt: converging signals for neurogenic hypertension. Curr Hypertens Rep (2007) 2.23
A new conceptual paradigm for the haemodynamics of salt-sensitive hypertension: a mathematical modelling approach. J Physiol (2012) 1.76
Current computational models do not reveal the importance of the nervous system in long-term control of arterial pressure. Exp Physiol (2009) 1.74
Phosphoinositide 3-kinase mediates enhanced spontaneous and agonist-induced contraction in aorta of deoxycorticosterone acetate-salt hypertensive rats. Circ Res (2002) 1.74
Splanchnic circulation is a critical neural target in angiotensin II salt hypertension in rats. Hypertension (2007) 1.71
Gene transfer of human guanosine 5'-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension. Circulation (2003) 1.65
Arterial 5-hydroxytryptamine transporter function is impaired in deoxycorticosterone acetate and Nomega-nitro-L-arginine but not spontaneously hypertensive rats. Hypertension (2006) 1.63
Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation (2003) 1.59
Endothelin receptor function in mesenteric veins from deoxycorticosterone acetate salt-hypertensive rats. J Hypertens (2002) 1.47
Low [Mg2+]e enhances arterial spontaneous tone via phosphatidylinositol 3-kinase in DOCA-salt hypertension. Hypertension (2003) 1.45
Serotonin and blood pressure regulation. Pharmacol Rev (2012) 1.41
Chronic angiotensin II infusion causes differential responses in regional sympathetic nerve activity in rats. Hypertension (2010) 1.39
Region-specific changes in sympathetic nerve activity in angiotensin II-salt hypertension in the rat. Exp Physiol (2009) 1.35
Neural mechanisms of angiotensin II-salt hypertension: implications for therapies targeting neural control of the splanchnic circulation. Curr Hypertens Rep (2011) 1.29
Whole body norepinephrine kinetics in ANG II-salt hypertension in the rat. Am J Physiol Regul Integr Comp Physiol (2008) 1.26
Chronic low-dose angiotensin II infusion increases venomotor tone by neurogenic mechanisms. Hypertension (2006) 1.25
Hypertension caused by prenatal testosterone excess in female sheep. Am J Physiol Endocrinol Metab (2007) 1.15
5-hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin Exp Pharmacol Physiol (2006) 1.15
Doxycycline, a matrix metalloprotease inhibitor, reduces vascular remodeling and damage after cerebral ischemia in stroke-prone spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol (2011) 1.10
A new signaling paradigm for serotonin: use of Crk-associated substrate in arterial contraction. Am J Physiol Heart Circ Physiol (2006) 1.07
Does enhanced respiratory-sympathetic coupling contribute to peripheral neural mechanisms of angiotensin II-salt hypertension? Exp Physiol (2010) 1.05
Reversal of genetic salt-sensitive hypertension by targeted sympathetic ablation. Hypertension (2013) 1.04
Tempol lowers blood pressure and sympathetic nerve activity but not vascular O2- in DOCA-salt rats. Hypertension (2004) 1.04
Loss of the aryl hydrocarbon receptor induces hypoxemia, endothelin-1, and systemic hypertension at modest altitude. Hypertension (2008) 1.03
The role of the subfornical organ in angiotensin II-salt hypertension in the rat. Exp Physiol (2011) 1.02
Increased O2*- production and upregulation of ETB receptors by sympathetic neurons in DOCA-salt hypertensive rats. Hypertension (2004) 1.02
5-Hydroxytryptamine lowers blood pressure in normotensive and hypertensive rats. J Pharmacol Exp Ther (2008) 1.02
Activation of ETB receptors increases superoxide levels in sympathetic ganglia in vivo. Am J Physiol Regul Integr Comp Physiol (2005) 1.00
Chemerin connects fat to arterial contraction. Arterioscler Thromb Vasc Biol (2013) 0.99
Differential alterations in sympathetic neurotransmission in mesenteric arteries and veins in DOCA-salt hypertensive rats. Auton Neurosci (2003) 0.99
Endothelin-1 stimulates arterial VCAM-1 expression via NADPH oxidase-derived superoxide in mineralocorticoid hypertension. Hypertension (2003) 0.98
NADPH oxidase-derived superoxide augments endothelin-1-induced venoconstriction in mineralocorticoid hypertension. Hypertension (2003) 0.98
Large-conductance Ca2+-activated K+ channel beta1-subunit knockout mice are not hypertensive. Am J Physiol Heart Circ Physiol (2010) 0.97
A comparison of arteries and veins in oxidative stress: producers, destroyers, function, and disease. Exp Biol Med (Maywood) (2007) 0.97
A serotonergic system in veins: serotonin transporter-independent uptake. J Pharmacol Exp Ther (2008) 0.96
Morphological and biochemical characterization of remodeling in aorta and vena cava of DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol (2007) 0.96
The serotonin transporter is present and functional in peripheral arterial smooth muscle. J Cardiovasc Pharmacol (2004) 0.96
Whole grape intake impacts cardiac peroxisome proliferator-activated receptor and nuclear factor kappaB activity and cytokine expression in rats with diastolic dysfunction. Hypertension (2010) 0.96
Rho/Rho kinase and phosphoinositide 3-kinase are parallel pathways in the development of spontaneous arterial tone in deoxycorticosterone acetate-salt hypertension. J Pharmacol Exp Ther (2004) 0.96
Vascular reactivity, 5-HT uptake, and blood pressure in the serotonin transporter knockout rat. Am J Physiol Heart Circ Physiol (2008) 0.96
Splanchnic sympathetic nerves in the development of mild DOCA-salt hypertension. Am J Physiol Heart Circ Physiol (2011) 0.94
Time-dependent changes in autonomic control of splanchnic vascular resistance and heart rate in ANG II-salt hypertension. Am J Physiol Heart Circ Physiol (2011) 0.94
Arteries and veins desensitize differently to endothelin. J Cardiovasc Pharmacol (2004) 0.92
Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists. Br J Pharmacol (2002) 0.92
Nitric oxide-independent effects of tempol on sympathetic nerve activity and blood pressure in DOCA-salt rats. Am J Physiol Heart Circ Physiol (2002) 0.91
The interdependence of endothelin-1 and calcium: a review. Clin Sci (Lond) (2010) 0.91
Effects of PPAR-gamma ligands on vascular smooth muscle marker expression in hypertensive and normal arteries. Am J Physiol Heart Circ Physiol (2004) 0.90
Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein. J Pharmacol Exp Ther (2009) 0.90
Vena cava and aortic smooth muscle cells express transglutaminases 1 and 4 in addition to transglutaminase 2. Am J Physiol Heart Circ Physiol (2012) 0.90
Differences in sympathetic neuroeffector transmission to rat mesenteric arteries and veins as probed by in vitro continuous amperometry and video imaging. J Physiol (2007) 0.90
Upregulation of arterial serotonin 1B and 2B receptors in deoxycorticosterone acetate-salt hypertension. Hypertension (2002) 0.89
Chronic estradiol-17β exposure increases superoxide production in the rostral ventrolateral medulla and causes hypertension: reversal by resveratrol. Am J Physiol Regul Integr Comp Physiol (2011) 0.89
5-hydroxtryptamine receptors in systemic hypertension: an arterial focus. Cardiovasc Ther (2011) 0.89
Vascular reactivity of mesenteric arteries and veins to endothelin-1 in a murine model of high blood pressure. Vascul Pharmacol (2005) 0.88
PI3-kinase upregulation and involvement in spontaneous tone in arteries from DOCA-salt rats: is p110delta the culprit? Hypertension (2004) 0.88
Cyclooxygenase, p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase MAPK, Rho kinase, and Src mediate hydrogen peroxide-induced contraction of rat thoracic aorta and vena cava. J Pharmacol Exp Ther (2006) 0.88
Cardiovascular depression in rats exposed to inhaled particulate matter and ozone: effects of diet-induced metabolic syndrome. Environ Health Perspect (2013) 0.88
Drug Delivery: Enabling Technology for Drug Discovery and Development. iPRECIO Micro Infusion Pump: Programmable, Refillable, and Implantable. Front Pharmacol (2011) 0.88
Arterial expression of 5-HT2B and 5-HT1B receptors during development of DOCA-salt hypertension. BMC Pharmacol (2003) 0.87
Activation of vascular BK channel by tempol in DOCA-salt hypertensive rats. Hypertension (2005) 0.87
Mild DOCA-salt hypertension: sympathetic system and role of renal nerves. Am J Physiol Heart Circ Physiol (2011) 0.87
Vascular BK channel deficiency exacerbates organ damage and mortality in endotoxemic mice. J Cardiovasc Pharmacol (2012) 0.87
Activation of potassium channels by tempol in arterial smooth muscle cells from normotensive and deoxycorticosterone acetate-salt hypertensive rats. Hypertension (2006) 0.87
Characterization of vabicaserin (SCA-136), a selective 5-hydroxytryptamine 2C receptor agonist. J Pharmacol Exp Ther (2011) 0.86
Methyl-beta-cyclodextrin prevents angiotensin II-induced tachyphylactic contractile responses in rat aorta. J Pharmacol Exp Ther (2007) 0.86
Gene transfer of endothelial NO synthase and manganese superoxide dismutase on arterial vascular cell adhesion molecule-1 expression and superoxide production in deoxycorticosterone acetate-salt hypertension. Arterioscler Thromb Vasc Biol (2002) 0.86
Serotonin transporter interacts with the PDGFβ receptor in PDGF-BB-induced signaling and mitogenesis in pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol (2010) 0.86
5-hydroxytryptamine (5-HT) reduces total peripheral resistance during chronic infusion: direct arterial mesenteric relaxation is not involved. BMC Pharmacol (2012) 0.86
Pleiotropic effects of hydrogen peroxide in arteries and veins from normotensive and hypertensive rats. Hypertension (2006) 0.85
Increased sympathetic venoconstriction and reactivity to norepinephrine in mesenteric veins in anesthetized DOCA-salt hypertensive rats. Am J Physiol Heart Circ Physiol (2007) 0.85
Lack of the serotonin transporter (SERT) reduces the ability of 5-hydroxytryptamine to lower blood pressure. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.85
Impaired function of alpha2-adrenergic autoreceptors on sympathetic nerves associated with mesenteric arteries and veins in DOCA-salt hypertension. Am J Physiol Heart Circ Physiol (2003) 0.85
Upregulated function of phosphatidylinositol-3-kinase in genetically hypertensive rats: a moderator of arterial hypercontractility. Clin Exp Pharmacol Physiol (2005) 0.85
5-Hydroxytryptamine(2B) receptor function is enhanced in the N(omega)-nitro-L-arginine hypertensive rat. J Pharmacol Exp Ther (2002) 0.84
Modification of proteins by norepinephrine is important for vascular contraction. Front Physiol (2010) 0.84
One-month serotonin infusion results in a prolonged fall in blood pressure in the deoxycorticosterone acetate (DOCA) salt hypertensive rat. ACS Chem Neurosci (2012) 0.84
Big ET-1 processing into vasoactive peptides in arteries and veins. Vascul Pharmacol (2007) 0.84
Endothelin-1-induced contraction in veins is independent of hydrogen peroxide. Am J Physiol Heart Circ Physiol (2005) 0.84
Normoxia vs. hyperoxia: impact of oxygen tension strategies on outcomes for patients receiving cardiopulmonary bypass for routine cardiac surgical repair. J Extra Corpor Technol (2006) 0.84
Effect of global and regional sympathetic blockade on arterial pressure during water deprivation in conscious rats. Am J Physiol Heart Circ Physiol (2012) 0.83
Vasopressin induces vascular superoxide via endothelin-1 in mineralocorticoid hypertension. Hypertension (2002) 0.83
A comparison of reactive oxygen species metabolism in the rat aorta and vena cava: focus on xanthine oxidase. Am J Physiol Heart Circ Physiol (2008) 0.83
Body distribution of infused serotonin in rats. Clin Exp Pharmacol Physiol (2009) 0.83
Alterations in sympathetic neuroeffector transmission to mesenteric arteries but not veins in DOCA-salt hypertension. Auton Neurosci (2009) 0.83
Pharmacological endothelin receptor interaction does not occur in veins from ET(B) receptor deficient rats. Vascul Pharmacol (2008) 0.83